Effects of Sodium Glucose Cotransporter-2 Inhibitors on Serum Uric Acid in Type 2 Diabetes Mellitus

被引：46

作者：

Ahmadieh, Hala ^{[1
]}

Azar, Sami ^{[2
]}

机构：

[1] Beirut Arab Univ, Internal Med Dept, Clin Sci Dept, Fac Med, Beirut, Lebanon

[2] Amer Univ Beirut, Dept Internal Med, Div Endocrinol, 3 Dag Hammarskjold Plaza,8th Floor, New York, NY 10017 USA

来源：

DIABETES TECHNOLOGY & THERAPEUTICS | 2017年 / 19卷 / 09期

关键词：

Hyperuricemia; Metabolic syndrome; Cardiovascular disease; SGLT2; INHIBITORS; SUBCLINICAL ATHEROSCLEROSIS; METABOLIC SYNDROME; GLYCEMIC CONTROL; BLOOD-PRESSURE; DOUBLE-BLIND; DAPAGLIFLOZIN; HYPERURICEMIA; EMPAGLIFLOZIN; EFFICACY;

D O I：

10.1089/dia.2017.0070

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Hyperuricemia has been linked to metabolic syndrome, cardiovascular disease, and chronic kidney disease. Hyperuricemia and type 2 diabetes mellitus were inter-related, type 2 diabetes mellitus was more at risk of having a higher serum uric acid level, and also individuals with higher serum uric acid had higher risk of developing type 2 diabetes in the future. Insulin resistance seems to play an important role in the causal relationship between metabolic syndrome, type 2 diabetes, and hyperuricemia. Oral diabetic drugs that would have additional beneficial effects on reducing serum uric acid levels are of importance. Selective SGLT2 inhibitors were extensively studied in type 2 diabetes mellitus and were found to have improvement of glycemic control, in addition to their proven metabolic effects on weight and blood pressure. Additional beneficial effect of SGLT2 inhibitors on serum uric acid level reduction is investigated. Recently, data have been accumulating showing that they have additional beneficial effects on serum uric acid reduction. As for the postulated mechanism, serum uric acid decreased in SGLT2 inhibitor users as a result of the increase in the urinary excretion rate of uric acid, due to the inhibition of uric acid reabsorption mediated by the effect of the drug on the GLUT9 isoform 2, located at the collecting duct of the renal tubule.

引用

页码：507 / 512

页数：6

共 50 条

[1]

SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study [J].

Abdul-Ghani, Muhammad ;

Del Prato, Stefano ;

Chilton, Robert ;

DeFronzo, Ralph A. .

DIABETES CARE, 2016, 39 (05) :717-725

[2]

[Anonymous], 2015, DRUG SAF COMM FDA WA

[3]

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial [J].

Bailey, Clifford J. ;

Gross, Jorge L. ;

Hennicken, Delphine ;

Iqbal, Nayyar ;

Mansfield, Traci A. ;

List, James F. .

BMC MEDICINE, 2013, 11

[4]

Serum Uric Acid Levels and the Risk of Type 2 Diabetes: A Prospective Study [J].

Bhole, Vidula ;

Choi, Jee Woong J. ;

Kim, Sung Woo ;

de Vera, Mary ;

Choi, Hyon .

AMERICAN JOURNAL OF MEDICINE, 2010, 123 (10) :957-961

[5]

Billiet L, 2014, ISRN RHEUMATOL, DOI DOI 10.1155/2014/852954

[6]

Renal Transport of Uric Acid: Evolving Concepts and Uncertainties [J].

Bobulescu, Alexandru ;

Moe, Orson W. .

ADVANCES IN CHRONIC KIDNEY DISEASE, 2012, 19 (06) :358-371

[7]

Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin [J].

Bolinder, J. ;

Ljunggren, O. ;

Johansson, L. ;

Wilding, J. ;

Langkilde, A. M. ;

Sjostrom, C. D. ;

Sugg, J. ;

Parikh, S. .

DIABETES OBESITY & METABOLISM, 2014, 16 (02) :159-169

[8]

SLC2A9 Is a High-Capacity Urate Transporter in Humans [J].

Caulfield, Mark J. ;

Munroe, Patricia B. ;

O'Neill, Deb ;

Witkowska, Kate ;

Charchar, Fadi J. ;

Doblado, Manuel ;

Evans, Sarah ;

Eyheramendy, Susana ;

Onipinla, Abiodun ;

Howard, Philip ;

Shaw-Hawkins, Sue ;

Dobson, Richard J. ;

Wallace, Chris ;

Newhouse, Stephen J. ;

Brown, Morris ;

Connell, John M. ;

Dominiczak, Anna ;

Farrall, Martin ;

Lathrop, G. Mark ;

Samani, Nilesh J. ;

Kumari, Meena ;

Marmot, Michael ;

Brunner, Eric ;

Chambers, John ;

Elliott, Paul ;

Kooner, Jaspal ;

Laan, Maris ;

Org, Elin ;

Veldre, Gudrun ;

Viigimaa, Margus ;

Cappuccio, Francesco P. ;

Ji, Chen ;

Iacone, Roberto ;

Strazzullo, Pasquale ;

Moley, Kelle H. ;

Cheeseman, Chris .

PLOS MEDICINE, 2008, 5 (10) :1509-1523

[9]

Effect of Urate-Lowering Therapy on All-Cause and Cardiovascular Mortality in Hyperuricemic Patients without Gout: A Case-Matched Cohort Study [J].

Chen, Jiunn-Horng ;

Lan, Joung-Liang ;

Cheng, Chi-Fung ;

Liang, Wen-Miin ;

Lin, Hsiao-Yi ;

Tsay, Gregory J. ;

Yeh, Wen-Ting ;

Pan, Wen-Harn .

PLOS ONE, 2015, 10 (12)

[10]

SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria [J].

Chino, Yukihiro ;

Samukawa, Yoshishige ;

Sakai, Soichi ;

Nakai, Yasuhiro ;

Yamaguchi, Jun-ichi ;

Nakanishi, Takeo ;

Tamai, Ikumi .

BIOPHARMACEUTICS & DRUG DISPOSITION, 2014, 35 (07) :391-404

← 1 2 3 4 5 →